ES2106772T3 - Variantes de pai-2. - Google Patents

Variantes de pai-2.

Info

Publication number
ES2106772T3
ES2106772T3 ES91901253T ES91901253T ES2106772T3 ES 2106772 T3 ES2106772 T3 ES 2106772T3 ES 91901253 T ES91901253 T ES 91901253T ES 91901253 T ES91901253 T ES 91901253T ES 2106772 T3 ES2106772 T3 ES 2106772T3
Authority
ES
Spain
Prior art keywords
variants
pai
pct
sec
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91901253T
Other languages
English (en)
Inventor
Neil Howard Goss
Michael Andrew Richardson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotech Australia Pty Ltd
Original Assignee
Biotech Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Australia Pty Ltd filed Critical Biotech Australia Pty Ltd
Application granted granted Critical
Publication of ES2106772T3 publication Critical patent/ES2106772T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

SE PRESENTAN VARIANTES DE UN ACTIVADOR INHIBIDOR DE PLASMA PAI-2 EN QUE LA ZONA DE RESIDUOS AMINOACIDOS (66-98) ES ALTERADA PARA ELIMINAR EL EMPLAZAMIENTO DE PROTEASA SENSITIVA. LAS VARIANTES DE LA INVENCION, MANTIENEN LA ACTIVIDAD BIOLOGICA DE PAI-2, Y AMINOACIDOS, POR ENCIMA DE 65 Y DE 99 PAI-2 EN PREPARADO. VARIANTES DE PAI-2 DE LA INVENCION, EN PREPARACION DE LABORATORIO, ASI COMO MOLECULAS DE DNA CODIFICANDO LAS VARIANTES DE LA INVENCION, CELULAS PATRON TRANSFORMADAS EXPRESANDO LAS VARIANTES DE LA INVENCION, COMPOSICION Y DIAGNOSTICO CONJUNTO, O COMPRENDIENDO LAS VARIANTES DE LA INVENCION, ANTICUERPOS CONTRA LAS VARIANTES DE LA INVENCION Y PROCESOS PARA LA PRODUCCION DE DICHAS VARIANTES, MOLECULAS DNA PATRONES DE TRANSFORMACION Y ANTICUERPOS DE LA INVENCION.
ES91901253T 1989-12-20 1990-12-20 Variantes de pai-2. Expired - Lifetime ES2106772T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ792489 1989-12-20

Publications (1)

Publication Number Publication Date
ES2106772T3 true ES2106772T3 (es) 1997-11-16

Family

ID=3774424

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91901253T Expired - Lifetime ES2106772T3 (es) 1989-12-20 1990-12-20 Variantes de pai-2.

Country Status (10)

Country Link
US (1) US5444153A (es)
EP (1) EP0458937B1 (es)
JP (1) JP2567536B2 (es)
AT (1) ATE156859T1 (es)
AU (1) AU625018B2 (es)
DE (1) DE69031271T2 (es)
DK (1) DK0458937T3 (es)
ES (1) ES2106772T3 (es)
GR (1) GR3025330T3 (es)
WO (1) WO1991009124A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
DE4214215A1 (de) * 1992-04-30 1993-11-04 Behringwerke Ag Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen
DE4214999C2 (de) * 1992-05-06 1994-07-14 Behringwerke Ag Reinigung von Plasminogen-Aktivator-Inhibitor 2 durch Immunaffinitätschromatographie
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
CN1196701C (zh) * 1997-03-19 2005-04-13 埃莫里大学 1,3－氧硒戊环核苷的合成及抗人类免疫缺陷病毒和抗乙肝病毒活性
US5994309A (en) * 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
KR20010042402A (ko) 1998-04-01 2001-05-25 로잘란드 앤 칼도르 피부 상처의 치료를 위한 프로테아제 억제제의 용도
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
EP1066834A3 (de) * 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens
AUPQ380699A0 (en) * 1999-11-02 1999-11-25 Biotech Australia Pty Limited Protease inhibitors as modulators of periodontal wound healing
AUPQ582400A0 (en) * 2000-02-24 2000-03-16 Biotech Australia Pty Limited A method of treatment and agents for use therein
US8062637B2 (en) * 2000-05-08 2011-11-22 Morphosys Ag Methods of ameliorating inflammatory disease using an uPA antagonist
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6562572B1 (en) * 2000-09-27 2003-05-13 Mayo Foundation For Medical Education And Research Methods for amplifying nucleic acid sequences
US20110028397A1 (en) * 2007-11-30 2011-02-03 Toezser Jozsef Use of Urokinase Type Plasminogen Activator Inhibitors for the Treatment of Corneal Disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923807A (en) * 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
EP0192671B1 (en) * 1984-08-13 1993-12-29 Biotechnology Australia Pty. Ltd. Minactivin
IL81879A (en) * 1986-03-13 1994-07-31 Biotech Australia Pty Ltd Purification of minactivin for homogeneity, production of minactivin as recombinant techniques, and uses of homogeneous or recombinant minactivin
AU608752B2 (en) * 1986-03-13 1991-04-18 Australian National University, The Minactivin produced by recombinant dna technology
DE3722673A1 (de) * 1987-04-18 1989-01-19 Behringwerke Ag Fuer plasminogenaktivator-inhibitor, typ 2 (pai-2) codierende dna
ES2104610T3 (es) * 1989-09-05 1997-10-16 Biotech Australia Pty Ltd Proceso para la preparacion de pai-2.

Also Published As

Publication number Publication date
WO1991009124A1 (en) 1991-06-27
AU625018B2 (en) 1992-06-25
EP0458937B1 (en) 1997-08-13
EP0458937A1 (en) 1991-12-04
DE69031271T2 (de) 1998-02-26
ATE156859T1 (de) 1997-08-15
EP0458937A4 (en) 1992-04-01
DE69031271D1 (de) 1997-09-18
AU6967191A (en) 1991-07-18
GR3025330T3 (en) 1998-02-27
JPH04503761A (ja) 1992-07-09
JP2567536B2 (ja) 1996-12-25
US5444153A (en) 1995-08-22
DK0458937T3 (da) 1998-02-23

Similar Documents

Publication Publication Date Title
ES2106772T3 (es) Variantes de pai-2.
Potempa et al. The inactivation of human plasma alpha 1-proteinase inhibitor by proteinases from Staphylococcus aureus.
Tokunaga et al. The factor V-activating enzyme (RVV-V) from Russell's viper venom. Identification of isoproteins RVV-V alpha,-V beta, and-V gamma and their complete amino acid sequences.
Vissers et al. Cleavage and inactivation of alpha 1-antitrypsin by metalloproteinases released from neutrophils.
Potempa et al. Proteolytic inactivation of alpha-1-anti-chymotrypsin. Sites of cleavage and generation of chemotactic activity.
DE60029230T2 (de) Dipeptidyl-peptidasen
DE69027024T2 (de) Matritzenmetalloproteinasepeptide, ihre wirkung in diagnose und therapie
Neves-Ferreira et al. Isolation and characterization of DM40 and DM43, two snake venom metalloproteinase inhibitors from Didelphis marsupialis serum
Samuels et al. A cuticle-degrading proteinase from the moulting fluid of the tobacco hornworm, Manduca sexta
Glover et al. Synthetic peptide inhibitors of complement serine proteases—I. Identification of functionally equivalent protease inhibitor sequences in serpins and inhibition of C1s and D
ES8607243A1 (es) Esteres de aminoacidos y de peptidos cromogenos
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
Sanchez et al. Structural and functional characterization of a P-III metalloproteinase, leucurolysin-B, from Bothrops leucurus venom
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
Bradford et al. Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain.
de Agostini et al. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.
DK0446315T3 (da) Fremgangsmåde til fremstilling af PAI-2
Lindsay et al. Isolation and characterization of ovochymase, a chymotrypsin-like protease released during Xenopus laevis egg activation
Mole et al. Structural evidence that complement factor B constitutes a novel class of serine protease.
JPH02147954A (ja) ヒトの血清または血漿におけるオステオカルシンの決定法
Abrahamson et al. Modification of cystatin C activity by bacterial proteinases and neutrophil elastase in periodontitis.
Briet et al. Cleavage and activation of human prothrombin by Echiscarinatus venom
Samama et al. Crystallization and preliminary crystallographic data for bovine antithrombin III
Gramse et al. Degradation of human fibrinogen by chymotrypsin-like neutral protease from human granulocytes
Davies et al. Evidence that kidney lysosomal proteinases degrade the collagen of glomerular basement membrane

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 458937

Country of ref document: ES